Cargando…
Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines
Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial ki...
Autores principales: | Lum, Lawrence G., Thakur, Archana, Elhakiem, Abdalla, Alameer, Lena, Dinning, Emily, Huang, Manley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214537/ https://www.ncbi.nlm.nih.gov/pubmed/32432032 http://dx.doi.org/10.3389/fonc.2020.00544 |
Ejemplares similares
-
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021) -
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022) -
GREP in InDesign CS3/CS4
por: Kahrel, Peter
Publicado: (2009) -
Studies on the decay of $^{120}$Cs, $^{118}$Cs and $^{116}$Cs
por: Batsch, T, et al.
Publicado: (1976) -
Photoshop CS3
por: Weinmann, Elaine, et al.
Publicado: (2008)